Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 706 participants.
Also called NCT02461589
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 706 participants
- Sponsor
- Registry
-
NCT02461589 -
2014-003196-39
-
- Main results
- A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Canada, Czechia, Germany, Malaysia, Russia, Serbia, South Africa, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02461589. Randomized; double masking; primary purpose treatment. Start 2015-09-21 (actual); primary completion 2016-10-13 (actual). Results posted on 2018-01-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- semaglutide
- Intervention (Drug)
- liraglutide
- Intervention (Drug)
- placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02461589- Content hash
6a2b53b5233ee68f5a3901867940ca809349b030e9f200a66a8c2f20d23e2f02